{"disease":{"id":"e-coli-infections","name":"e coli infections"},"drugs":{"marketed":[{"drug_id":"ampicillin","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"ceftazidime","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"tazicef","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"ceftazidim","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04087681","title":"Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)","phase":"","overall_status":"COMPLETED","enrollment_count":4479,"lead_sponsor_name":"MJM Bonten","has_results":false},{"nct_id":"NCT04694235","title":"Egg Intervention During Pregnancy in Indonesia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":702,"lead_sponsor_name":"SEAMEO Regional Centre for Food and Nutrition","has_results":false},{"nct_id":"NCT03441893","title":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT03303937","title":"Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients","phase":"","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Hôpital Louis Mourier","has_results":false},{"nct_id":"NCT06815549","title":"An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis\"","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":280,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT03349814","title":"Explanations for Negative Laparoscopic Appendectomies and Normal Laparoscopies","phase":"","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT05098600","title":"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Faculty Hospital Kralovske Vinohrady","has_results":false},{"nct_id":"NCT03869593","title":"Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria","phase":"","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06252428","title":"Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals","phase":"","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT03800147","title":"Effects of Nutritional Fat on the Growth of Intestinal E. Coli","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT05277350","title":"A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"SNIPR Biome Aps.","has_results":false},{"nct_id":"NCT07280598","title":"Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT06938867","title":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"SNIPR Biome Aps.","has_results":false},{"nct_id":"NCT04626947","title":"Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"David Binion, MD","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}